The research team separated the hard-to-kill stem cells from the general glioblastoma population by attracting the stem cells to a microchip coated with antibodies.
The drug-loaded nanocapsule is coated with an antibody that specifically targets activated platelets, the cells that form blood clots,
#Detecting HIV diagnostic antibodies with DNA nanomachines Detecting HIV diagnostic antibodies with DNA nanomachines (Nanowerk News) New research may revolutionize the slow,
cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and autoimmune diseases such as rheumatoid arthritis and HIV.
"whose customized modifications enable it to recognize a specific target antibody. Their new approach, which they described this month in Angewandte Chemie("A Modular, DNA-Based Beacon for Single-Step Fluorescence Detection of Antibodies and Other Proteins"),
"promises to support the development of rapid, low-cost antibody detection at the point-of-care, eliminating the treatment initiation delays
and increasing healthcare costs associated with current techniques. New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and autoimmune diseases such as rheumatoid arthritis and HIV.
An international team of researchers have designed and synthesized a nanometer scale DNA"machine "whose customized modifications enable it to recognize a specific target antibody.
Their new approach, which they described this month in Angewandte Chemie, promises to support the development of rapid,
low-cost antibody detection at the point-of-care, eliminating the treatment initiation delays and increasing healthcare costs associated with current techniques.
The light-generating DNA antibody detecting nanomachine is illustrated here in action, bound to an antibody.
Marco Tripodi) The binding of the antibody to the DNA machine causes a structural change (or switch),
and is rapid-acting within five minutes-enabling the targeted antibodies to be detected easily, even in complex clinical samples such as blood serum."
so that it can detect a huge range of antibodies, this makes our platform adaptable for many different diseases"."
""Our modular platform provides significant advantages over existing methods for the detection of antibodies,"added Prof.
which to make antibodies for pharmaceutical use. Researchers around the world can access Professor Waterhouse's open source website
Detecting Alzheimer antibodies at the preclinical stage would give patients an opportunity to work with their physician to make lifestyle changes
Because it tests for antibodies, which is a bodily response, there is timeframe for false negatives.
"The drug-loaded nanocapsule is coated with an antibody that specifically targets activated platelets, the cells that form blood clots,
which is made up of antibodies (the tags that our immune system uses to mark viruses and bacteria as invaders) and chemicals that cause the test to change colours if these antibodies bind to Ebola proteins in the sample.
The big innovation: To make the test stable, Hallisey used silk fibres to stabilise the chemicals on card stock, allowing them to sit around at room temperature for up to three weeks
The three chemicals used to detect the Ebola protein-bound antibodies are added to separate corners of the paper (2, 3, 4 in the diagram below.
And the anti-Ebola antibodies are in the center. To run the test, the serum sample is added to the open corner (1). Then, one by one,
#Scientists have found a way to make leukaemia cells kill each other Researchers in the US have found an antibody that turns cancerous leukaemia cells into natural killer cells-a type of white blood cell that's able to seek out
His team had discovered recently that by exposing marrow cells to antibodies from other parts of the body,
Based on this knowledge, Learner and his colleagues started looking for an antibody that could transform cancerous leukaemia cells back into healthy bone marrow cells.
But instead they stumbled across a rare human antibody that has even more potential: it can actually turn leukaemia cells into cancer killers.
The antibody in question binds to a receptor called TPO-or thrombopoietin-which is found on most acute myeloid leukaemia cells.
When the researchers first exposed the leukaema cells to the antibody, they watched as it turned many of them into harmless immune cells known as dendritic cells.
when they continued to apply the antibody to the cells, a number of them developed further into cells very similar to natural killer (NK) cells,
"That antibody could have turned those acute myeloid leukaemia cells into a lot of other cell types, but somehow we were lucky enough to get NK cells,
Fortunately, the antibody only affected leukaemia cells, and not healthy bone marrow, which suggests that it could work as a targeted cancer therapy.
and Lerner's team is now trying to figure out exactly how the antibody works. But they're pretty keen to get the therapy into clinical trials soon."
The team is also screening for antibodies that could have a similar effect on other cancer types.
the body mobilizes to produce antibodies. Huo's test detects that immune response using gold nanoparticles about 10,000 times smaller than a freckle.
#Researchers deliver large particles into cells at high speed The researchers created a highly efficient automated tool that delivers nanoparticles, enzymes, antibodies, bacteria and other"large-sized"cargo into mammalian cells at the rate
along with those used for clinical diagnosis--using microbeads tagged with antibodies against three published markers of cervical cancer.
Based on the number of antibody-tagged microbeads binding to cells, D3 analysis promptly and reliably categorized biopsy samples as high-risk, low-risk or benign, with results matching those of conventional pathologic analysis
since Swedish biotech company Atlas Antibodies has shown interest in commercialising our findings, 'says Per-Henrik Edqvist.
The antibody blocks CTLA-4, a protein switch on the surface of T cells that, when turned on, dampens their activation.
Nivolumab, meanwhile, is an antibody that targets a protein known as PD-1, which is also found on the T cell surface.
"Testing for HIV-1 in whole bloodcurrent tests for HIV infection detect antibodies to HIV in the individual's blood.
However, because it takes up to several months for those antibodies to form, these tests do not detect individuals in the earliest stage of infection
HIV-1 antibodies are added to whole blood or plasma where they bind to the virus creating aggregates of antibody and viral lysate.
When added to the flexible chip the aggregates change the electrical conductivity of the chip, which gives a simple electrical readout indicating that the sample contains HIV-1.
The microfluidic channels were coated with an antibody that captures the CD4+T cells. A single drop of whole blood from a fingerprick was applied to the polyester film,
#Better way to engineer therapeutic proteins into antibodies Some proteins exist so fleetingly in the bloodstream that they can't be given effectively as therapies.
such as antibodies, can make them persist long enough to be useful. Now a team led by scientists at The Scripps Research Institute (TSRI) has devised an improved method for accomplishing this protein-engineering feat.
and its antibody host, selecting the rare ones that allow the inserted protein to fold
Making Leptin Last Longer Lerner's laboratory helped pioneer techniques for generating billions of different antibodies
and screening these large"antibody libraries"to find those that perform a desired function. The new work is an extension of that technology.
the team edited the genetic code of a standard human antibody to replace one of its target-grappling elements--a structure that normally would bind to a virus, for example--with the protein leptin.
if it were part of a larger structure such as an antibody.""The major challenge for Lerner, Peng and their colleagues was to design leptin into an antibody in such a way that it would fold up into a functional structure
despite being bound to its host protein at either end. Designing simple, highly flexible"junction"segments to join leptin to an antibody could work--a recent paper by a group including TSRI's Peter Schultz,
Scripps Family Chair Professor of Chemistry, described such a feat. But Lerner's team reasoned that a selection-based design of these junctions would be a more general approach to making useful protein-in-protein molecules.
The Power of Large Numbers Using their established techniques for generating large libraries of variant antibodies
the team made nearly 30 million versions of the leptin-in-antibody protein, each version having a different amino-acid sequence for its junction segments.
and function properly, the researchers used a selection system that they had developed previously for finding therapeutic antibodies in large antibody libraries.
First they employed viral vectors to insert the leptin-in-antibody DNA into test cells that contain leptin receptors.
When one of the resulting leptin-in-antibody proteins successfully activated a leptin receptor in its test cell,
The cells whose beacon signals rose above a certain threshold were analyzed for the leptin-in-antibody DNA they contained,
until the process yielded the leptin-in-antibody protein that did best at activating the leptin receptor.
As is often the case for antibodies the leptin-in-antibody protein effectively could not cross from the bloodstream into the brain
and thus could not hit all of leptin's neuronal targets --and so its effects at reducing eating
But, in principle, antibodies can be modified to enable them to cross the blood-brain barrier more easily, and the team is working on that now.
the researchers also used it to"selection-design"an antibody that incorporates the growth and reproductive hormone FSH
The resulting FSH-in-antibody protein showed activity against the FSH receptor that was virtually the same as the natural hormone's The team is now working to improve their FSH-and leptin-in-antibody proteins,
and to design entirely new protein-in-antibody molecules s
#Engineers'sandwich'atomic layers to make new materials for energy storage The scientists whose job it is to test the limits of what nature--specifically chemistry--will allow to exist, just set up shop on some new real estate on the Periodic table.
#Scientists create designer proteins that control enzyme activity Scientists from the University of Chicago have developed a novel approach to control the activity of enzymes through the use of synthetic, antibody-like proteins known as monobodies.
Koide and his colleagues approached this problem by leveraging their longstanding expertise in designing monobodies--compact proteins that function as synthetic antibodies.
Like antibodies, monobodies recognize and bind to specific target proteins, serving as a marker or affecting function.
Coupled with their small size (around 15 times smaller than an antibody) and simple structure,
Anti-enolase antibodies interfere with the invasion, inhibiting parasite growth and transmission. A pentapeptide insert of parasite enolase, conserved in all Plasmodia species,
In a recent breakthrough to combat malaria, a collaboration of Indian and American scientists have identified a malarial parasite protein that can be used to develop antibodies
antibodies against this small fragment can potentially have a dual benefit by blocking the multiplication cycle of the parasite in humans,
antibodies directed against it are likely to protect against all species of the parasite, "says Sneha Dutta,
#In first human study, new antibody therapy shows promise in suppressing HIV infection In the first results to emerge from HIV patient trials of a new generation of so-called broadly neutralizing antibodies,
or even preventing HIV infection. hiv antibodies In a person infected with HIV, there is an ongoing arms race between the virus and the body immune system.
Even as the body produces new antibodies that target the virus the virus is constantly mutating to escape,
finds that administration of a potent antibody, called 3bnc117, can catch HIV off guard and reduce viral loads.
HIV antibodies previously tested in humans had shown disappointing results. 3bnc117 belongs to a new generation of broadly neutralizing antibodies that potently fight a wide range of HIV strains. hat special about these antibodies is that they have activity against over 80 percent
Broadly neutralizing antibodies are produced naturally in some 10 to 30 percent of people with HIV,
By that time the virus in their bodies has evolved typically to escape even these powerful antibodies.
by isolating and then cloning these antibodies, researchers are able to harness them as therapeutic agents against HIV infections that have had less time to prepare.
Earlier work in the Nussenzweig lab had demonstrated that these potent antibodies could prevent or suppress infection in mouse and nonhuman primate models of HIV.
uninfected and HIV-infected individuals were given intravenously a single dose of the antibody and monitored for 56 days.
The drop in viral load depended on the individual starting viral load and also the sensitivity of their particular strains of HIV to the antibody.
This is the first time that the new generation of HIV antibodies has been tested in humans. Not only was a single dose of 3bn117 well tolerated and effective in temporarily reducing viral loads,
Researchers also believe that antibodies may be able to enhance the patient immune responses against HIV, which can in turn lead to better control of the infection.
In addition, antibodies like 3bnc117 may be able to kill viruses hidden in infected cells, which serve as viral reservoirs inaccessible to current antiretroviral drugs.
will need to be used in combination with other antibodies or antiretroviral drugs to keep infections under control. ne antibody alone,
like one drug alone, will not be sufficient to suppress viral load for a long time because resistance will arise,
an antibody therapy for HIV might require treatment just once every few months, compared to daily regimens of antiretroviral drugs that are now the front-line treatment for HIV. n contrast to conventional antiretroviral therapy,
antibody-mediated therapy can also engage the patient immune cells, which can help to better neutralize the virus,
If researchers can induce an uninfected person immune system to generate potent antibodies such as 3bnc117 it might be enough to block the HIV infection before it can be established.
Ongoing clinical research in Nussenzweig lab and The Rockefeller University Hospital aims to address the impact of additional broadly neutralizing antibodies, alone or in combination, on viral load in HIV-infected patients.
such as surface markers or proteins, with flourescent probes attached to antibodies and pass those cells through lasers.
Flow cytometry allows researchers to use 8 to 10 fluorescently labeled markers typically antibodies to capture data about key cell features.
35 million people are infected with HIV-1 worldwide. e found that people infected with the HIV-1 virus have naturally occurring antibodies that have the potential to kill the infected cells.
We just have to give them a little push by adding a tiny molecule that acts as a can opener to force the viral envelope to expose regions recognized by the antibodies,
The antibodies that are naturally present after the infection can then target the infected cells
then kill the infected cells with this molecule and the already present antibodies, argues Finzi,
through antibodies that are easy to generate and using this new family of molecules. Furthermore, this discovery opens the way for the development of strategies to eliminate the viral reservoirs of individuals already infected.
PNA-antibodies detect initially the diseased cells (red) and accumulate at the tumor site. Afterwards the radioactively labeled probes (blue) selectively bind to them by specific base pairing.
The new method first sends out an antibody as a pyto detect the diseased cells and then binds to them.
This antibody in turn attracts a subsequently administered radioactively labeled probe. The scientists could then clearly visualize the tumor by utilizing a tomographic method.
The human immune system forms antibodies that protect the body from pathogens. Antibodies can also, however, be produced in a laboratory to precisely bind to tumor cells.
They are used in cancer research to detect and fight malignant tumors. For example, antibodies can serve as transport vehicles for radionuclides, with
which the affected regions can be visualized or can even be damaged. Until recently, a stumbling block has been their large molecular mass. his causes them to circulate in the body for too long before they reach the diseased cells
The researchers fall back on the cetuximab antibody as the scout, which binds selectively to the epidermal growth factor receptor (EGFR).
Clear Visualizationthe Dresden researchers combined the antibody with a peptide nucleic acid (PNA) derivative which Prof Gilles Gasser and Prof Nils Metzler-Nolte developed together with their respective working groups in Switzerland
the scientists first injected the PNA-EGFR antibody into tumor-bearing mice and gave this pytime to accumulate at the tumor site.
labeled with the radioactive substance technetium-99m. mages we took using single photon emission computed tomography show that both the antibody
we can overcome limitations of conventional, radioactively marked antibodies. According to the researchers, it will, however, take some time before the combination of PNA antibodies
and their matching PNA counterparts can be used in diagnosing tumors in humans. ur results however show that the PNAS we tested are suitable candidates for further preclinical studies, Stephan sums up.
Two recent studies pointed to possible flaws in the methods used to identify irisin, with commercially available antibodies.
that does not rely on antibodies, to precisely measure how much irisin increases in people after exercise. he data are compelling
and his team create using monoclonal antibodies antibodies designed to bind to proteins originating in only one type of cell.
the antibody-drug burrows inside them to release a toxic payload. ou add an antibody with a drug on it
After about an hour, the SAS1B-marked antibodies reach compartments inside the cell and release the drug payload, triggering changes that result in cell death within a few days.
scientists linked an antibody with a derivative of a group of antibiotics called rifamycin. This resulting drug proved to be a powerful new treatment against Staphylococcus aureus;
What's truly different here is that unlike the related antibiotic rifampicin the linked antibody-antibiotic unit can kill Staphylococcus bacteria inside cells.
'Can we tag the bacteria with antibodies armed with really potent antibiotics and kill these pathogens inside the cell?'"
Antibodies are made, of course, by the immune system but for the last several decades, biotechnology companies have made them as well.
Genentech manufactured antibodies based on those the immune system makes to combat staph infections. Then, the researchers attached the antibiotics to the antibody by using amino acids as glue.
When combined the drug becomes far better at specifically targeting staph at specifically targeting Staph bacteria compared with conventional antibiotics."
Still, the act of combining two different weapons antibodies and antibiotics to fight off infections is an intriguing idea.
The engineered cells contain an antibody-like protein known as a chimeric antigen receptor (CAR) which is designed to bind to a protein called CD19 found on the surface of B cells including the cancerous B cells that characterize several types of leukemia.
and antibodies that can shut it down, "he says.""We desperately need solutions to prevent HIV infection,
They also saw that antibodies known to exhibit some effectiveness acted to prevent gp120 from opening,
"The antibodies used in the crystallography study are ones that we observed to stop the dance of the HIV envelope proteins,
and where these antibodies bind provides an important step forward to understanding HIV's biology, "he says.
and less expensive to produce compared to the current most promising approach, antibodies. The Utah group has developed previously highly potent and broadly acting D-peptide inhibitors of HIV entry, currently in preclinical studies,
In order to avoid other interfering species present in plasma the bead surface was modified chemically with an antibody that recognizes
Antibodies produced by the body against this protein also react with the main satiety hormone
Where this protein is present antibodies are produced against it by the body. These will also bind to the satiety hormone because of its structural homology to Clpb
Food intake and level of antibodies against melanotropin in the 1st group of mice which were given mutant E coli bacteria (not producing Clpb) did not change.
In contrast antibody level and food intake did vary in the 2nd group of animals which received E coli producing Clpb protein.
Plasma levels of antibodies to Clpb and melanotropin were higher in these patients. Furthermore their immunological response determined the development of eating disorders in the direction of anorexia or bulimia.
According to our initial observations it would indeed be possible to neutralise this bacterial protein using specific antibodies without affecting the satiety hormone they conclude.
and found that they could expand antigen-specific T cells at least as well as existing methods using antibody-coated beads.
are compounds far smaller than less common biological medicines like antibodies. They are developed using libraries of thousands or millions of known chemical substances.
Other forms of immunotherapy-the stimulation of the body's own immune system to fight cancer-using antibodies rather viruses,
Other forms of immunotherapy-the stimulation of the body's own immune system to fight cancer-using antibodies rather viruses,
Virscan works by screening the blood for antibodies against any of the 206 species of viruses known to infect humans.
The immune system ramps up production of pathogen-specific antibodies when it encounters a virus for the first time
and it can continue to produce those antibodies for years or decades after it clears an infection.
Antiviral antibodies in the blood find and bind to their target epitopes within the displayed peptides.
The scientists then retrieve the antibodies and wash away everything except for the few bacteriophage that cling to them.
they can identify which viral protein pieces were grabbed onto by antibodies in the blood sample. That tells the scientists which viruses a person's immune system has encountered previously
which has struggled so far to elicit antibodies (immune system molecules) that can effectively fight off different strains of the virus."The results are said pretty spectacular
or inactive version of the disease-causing microbe itself to trigger antibody production, immunisations with"native"HIV proteins are ineffective in triggering an effective immune response,
but slightly different proteins (immunogens) to train the body to produce broadly neutralizing antibodies against HIV-a twist on the traditional"booster shot,
The researchers showed that immunisation with eod-GT8 60mer produced antibody"precursors"with some of the traits necessary to recognize
"The vaccine appears to work well in our mouse model to'prime'the antibody response,
and efficiently than current tests which rely heavily on antibodies. The sensor chip, able to pick up on subtle differences in glycoprotein molecules,
The findings show how the rate of false readings that come with antibody based diagnosis can be reduced by the new technology that focuses on the carbohydrate part of the molecule.
and so we need technology that can discriminate between these subtle differences-where antibodies are not able to,
normally a small transparent plate resembling a honeycomb with 96 tiny wells. Specific antibodies are placed then into each well,
Blood samples are tested after specific antibodies that bind to antigens meet the blood in the embedded well portion of the plate.
The introduced antibodies contain enzymes whose substrates react chemically and cause a distinct change in color.
If you place antibodies to certain viruses on the cantilever, it'll capture the viral particles in the analyzed environment.
then affix the nanoparticles to antibodies targeting malignant tumors and put them in a liquid that cancer patients could take via a single injection.
The researchers developed a drug carrier that consists of polymeric nanoparticles coated with specialized antibodies that target a small conserved (i e.
or antibody fragments and allow its passage into the eye. Once inside it releases the drugs.
which rely heavily on antibodies. These antibodies are expensive to produce, subject to degeneration when exposed to environmental changes (such as high temperatures
or UV LIGHT) and more importantly, have a high rate of false-positive readings. Professor Paula Mendes said,
The findings, published in the journal Chemical science, show how the rate of false readings that come with antibody based diagnosis can be reduced by the smart technology that focuses on the carbohydrate part of the molecule.
and so we need technology that can discriminate between these subtle differences-where antibodies are not able to."
During a virus infection, your immune system generates antibodies designed to fight the virus. Each antibody recognises a tiny fragment of the virus
Virus-specific antibodies can be long-lived; often persisting many years after an infection has disappeared. So, your antibody repertoire represents a historical record of all of the viruses that have infected you.
This immunological catalogue has been used for years to identify past virus exposure, but the diagnostic tests routinely used have been limited to one,
Antibodies present in a drop of human blood could then be used as bait to go fishing in this phage pool-only bacteriophage that express protein fragments recognised by the antibodies in the blood sample will be caught.
#Scientists find molecular switch that creates long-term immunity Melbourne researchers have identified a protein responsible for preserving the antibody-producing cells that lead to long-term immunity after infection or vaccination.
Dr Kim Good-Jacobson, Professor David Tarlinton and colleagues from the Walter and Eliza Hall Institute discovered the presence of a protein called Myb was essential for antibody-producing plasma cells to migrate into bone marrow,
it can create plasma cells that secrete antibodies to specifically prevent future infections, generating immunity, "she said."
allowing them to continue producing antibodies to protect against future infections. Until now, it was known not why some plasma cells moved into the bone marrow,
improving the design of antibodies to better recognise invading pathogens in the future, "she said.""The Myb protein marks the plasma cells that produce high-quality antibodies for preservation."
"Professor Tarlinton said the discovery would mean researchers could now search for the trigger of Myb production
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011